GlassScriptPhysician profile
Sawyer B Haig
NPI 1629333919
$3,804.12
in general payments reported to CMS, 2019-2025
36 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $227 · 2021: $317 · 2022: $589 · 2023: $720 · 2024: $809 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $644.13 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $497.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $275.96 | 2021-2024 | |
| Lilly USA, LLC | $261.67 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.65 | 2019-2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $180.01 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $133.41 | 2019-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $123.26 | 2019-2020 | |
| Radius Health, INC. | $113.32 | 2023-2024 | Tymlos |
| Glaxosmithkline, LLC. | $111.40 | 2021-2024 | Shingrix, Boostrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $103.76 | 2022-2025 | |
| Amarin Pharma, INC. | $101.72 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $97.87 | 2021-2024 | Contrave, Onzetra Xsail |
| Abbvie INC. | $97.16 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $88.44 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $85.30 | 2022-2023 | Quviviq |
| Bioventus LLC | $81.62 | 2022 | |
| Allergan, INC. | $74.30 | 2019-2020 | |
| Dexcom, INC. | $52.98 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $49.91 | 2024-2025 | Cologuard Collection Kit |
| Alk-Abello, INC | $49.15 | 2023-2024 | Odactra, Ragwitek, Grastek |
| Almatica Pharma LLC | $43.95 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.40 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $34.31 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.51 | 2019 | |
| Astellas Pharma US INC | $29.46 | 2024 | Veozah |
| Medicure Pharma INC. | $27.38 | 2023 | Zypitamag |
| Amneal Pharmaceuticals LLC | $24.11 | 2022 | |
| Shield Therapeutics INC | $22.61 | 2023 | Accrufer |
| Eisai INC. | $21.12 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.98 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $18.51 | 2019 | |
| Emd Serono, INC. | $18.03 | 2024 | |
| Ascend Therapeutics US, LLC | $16.67 | 2023 | |
| Alnylam Pharmaceuticals INC. | $15.67 | 2022 | |
| Gilead Sciences, INC. | $15.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sawyer Haig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.